**Knowledge Check for eModule 3: Prevenar 13®** **(pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): The vaccination process**

This knowledge check consists of 10 questions, and should take a maximum of 15 minutes to complete.

Please read each question carefully, as the type of answer you need to give may vary.

Good luck.

This knowledge check is provided to you by Pfizer Ltd. The information covered is not intended to replace your guidelines, protocols and SOPs.

**Please note that the correct answer(s) to each question is in red.**

## Question 1

**True or False**

**You should only check that your anaphylaxis kit is accessible and full (with all components in-date) prior to vaccinating someone with a known allergy.**

* True
* False

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 2

**Select the correct answer**

**Prevenar 13® should be stored at temperatures…**

1. Between 2°C and 8°C
2. Between 15°C and 37°C
3. Between -20°C and 0°C
4. Between 0°C and 2°C

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 3

**True or false**

**If a potential recipient is immunocompromised you should inform them that they may have a reduced antibody response to Prevenar 13®.**

* True
* False

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 4

**Select all that apply**

**Lisa is a 37-year-old female. She is currently in good health, does not have a bleeding disorder and is not immunocompromised. She has read the Prevenar 13® Patient Information Leaflet and has given informed consent to receive Prevenar 13®.**

**What else would you need to know before you decided whether Lisa could potentially receive Prevenar 13®?**

1. Whether she has previously received a pneumococcal vaccination
2. Whether she is hypersensitive to any of the ingredients found in Prevenar 13®
3. Whether she received a polio vaccine as a child
4. Whether she is pregnant

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 5

**Select the correct answer**

**Doug is a 42-year-old male. He is in good health, has no known allergies, does not have bleeding disorder and is not immunocompromised. He has previously received Pneumococcal Polysaccharide Vaccine (PPV). He has read the Prevenar 13® Patient Information Leaflet and has given informed consent to receive Prevenar 13®.**

**What else would you need to know before you decided whether Doug could potentially receive Prevenar 13®?**

1. Whether he is colour-blind
2. Whether his young child has received Prevenar 13® recently
3. Whether he had chickenpox as a child
4. How long ago he received PPV

Reference:

Public Health England. The Green Book [2018]. Chapter 25: Pneumococcal. Available at <https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25> . Last accessed January 2020.

## Question 6

**Select the correct answer**

**After you shake Prevenar 13®, what colour should the liquid in the syringe be?**

1. Colourless
2. Pale yellow
3. Grey
4. White
5. Pale green

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 7

**Select the correct answer**

**Which muscle should Prevenar 13® preferably be administered into in adults?**

1. The pectoralis major muscle
2. The brachioradialis muscle
3. The deltoid muscle
4. The latissimus dorsi muscle

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 8

**True or False**

**Prior to injecting Prevenar 13®, the skin at the injection site should be bunched.**

* True
* False

Reference:

Public Health England. The Green Book [2013]. Chapter 4: Immunisation procedures. Available at https://www.gov.uk/government/uploads/system/uploads/  
attachment\_data/file/147915/Green-Book-Chapter-4.pdf. Last accessed January 2020.

## Question 9

**Select the correct answer**

**When administering Prevenar 13® intramuscularly, the needle should be inserted at a \_\_ angle.**

1. 90°
2. 60°
3. 45°
4. 30°

Reference:

Public Health England. The Green Book [2013]. Chapter 4: Immunisation procedures. Available at https://www.gov.uk/government/uploads/system/uploads/  
attachment\_data/file/147915/Green-Book-Chapter-4.pdf. Last accessed January 2020.

## Question 10

**Select all that apply**

**After administering Prevenar 13® you should…**

1. Remind recipients that they should report side effects to a healthcare professional and can also report them directly via the Yellow Card Scheme
2. Remind recipients that they should speak to a healthcare professional if they develop symptoms of a pneumococcal infection
3. Remind the recipient that, as with any vaccine, Prevenar 13® will not protect everyone who is vaccinated, and although Prevenar 13® helps to protect against 13 of the most harmful types of *Streptococcus pneumoniae*, it won’t protect against all types

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

**Additional information:** In pneumococcal-vaccine naïve adults aged 18-49 years, percentages of solicited local and systemic reactions were generally higher compared with older subjects (aged 50-59 and 60-64 years).

